You don't have javascript enabled. Good luck with that.
Skip to content
FOR US HEALTHCARE PROFESSIONALS

Strongly recommended by AAD and AAAAI guidelines as a systemic therapy for moderate-to-severe atopic dermatitis in adult patients1,2

Safety Results


The safety of Adbry was evaluated
in an extensive clinical program3

Week 16 Safety

Demonstrated safety profile

Adverse reactions occurring in ≥1% through Week 163

q2w=every 2 weeks; TCS=topical corticosteroid.

*Pooled analysis of ECZTRA 1 and 2.
†Analysis of ECZTRA 3 in which patients were on background TCS therapy.
‡Adbry 600 mg or placebo at Week 0, followed by Adbry 300 mg or placebo q2w.
§ Upper respiratory tract infection cluster includes upper respiratory tract infection, viral upper respiratory tract infection, pharyngitis, and nasopharyngitis; mainly reported as the common cold. ||Conjunctivitis cluster includes conjunctivitis and allergic conjunctivitis.
Injection-site reaction cluster includes pain, erythema, and swelling.
#Eosinophilia cluster includes eosinophilia and eosinophil count increase.

Know the NOs of Adbry3

NO warnings for arthralgia, psoriasis, or psoriatic arthritis in the Prescribing Information

NO adverse reactions for facial redness, facial reactions, or herpes zoster in the Prescribing Information

NO citrate in ingredients

NO requirement for initial lab testing or ongoing lab monitoring

NO boxed warning

Long-Term Safety

Summary of safety up to 4.5 years4,5

Overall frequency of most common AEs (≥2%) occurring more frequently with Adbry compared to placebo4*

  • Safety profile over 4.5 years was consistent with initial treatment period4,5
  • Discontinuation rates due to adverse events remained low4,5‡

*Pooled safety analysis set included patients from ECZTRA 1-3 and 5-8. † Safety analysis set combining the parent trials with the subsequent ECZTEND trial including patients from first dose of Adbry until end of Adbry exposure or the ECZTEND data cut-off (April 30, 2022). ‡ Discontinuation rate was 5.3% (IR 2,7).

AE=adverse event; IR=incidence rate (n/100PYE); PYE=patient-years of exposure.

IN THE ECZTEND TRIAL:
No new safety signals over 6 years4-6§

IN THE ECZTEND TRIAL:
No new safety signals over 6 years4-6§

§ Up to 1 year in parent trials plus up to 5 years in ECZTEND.